Conference Coverage: ASCO 2022 – Focus on Breast Cancer
Expert perspectives on the latest therapeutic developments, treatment approaches, and implications for clinical decision-making coming out of the ASCO 2022 conference.
Adam Brufsky, MD, PhD, FACP
Magee-Womens Cancer Program at the UPMC Hillman Cancer Center, Pittsburgh, PA, USA
Giuseppe Curigliano, MD, PhD
University of Milano
Mark D. Pegram, MD
Stanford Cancer Institute
Peter A. Kaufman, MD
The University of Vermont Medical Center
KEY TAKEAWAYS AND STRATEGIC INSIGHTS
- Updates of Neoadjuvant Therapies in Breast Cancer
- CDK4/6 Inhibitors in the Treatment of HR+/HER2– Breast Cancer
- Novel Therapeutic Approaches for HR+/HER2– Breast Cancer
- Evolving Treatments for HER2+/HR– Breast Cancer
Complete the form below to receive additional information.